"Direct Removal of Brain Waste"... A New Approach to Alzheimer's Treatment [Reading Science]

A new therapeutic strategy has been proposed to enable brain cells to directly recognize and eliminate amyloid-beta (Aβ), a substance identified as a key cause of Alzheimer's disease. This approach applies chimeric antigen receptor (CAR) technology, previously used in immune cell therapies, to brain cells, and is being evaluated as a different approach from conventional antibody treatments.

A research team at Washington University School of Medicine in St. Louis, United States, introduced the CAR gene into astrocytes and presented a therapeutic strategy (CAR-A) for removing amyloid-beta. The results were published in the international journal Science on March 6, 2026 (Korea Standard Time).

Reference photo to aid understanding of the article. Provided by Getty Images Bank. Yonhap News Agency

원본보기 아이콘

The researchers engineered astrocytes to express the CAR gene designed to recognize amyloid-beta, enabling these cells to directly seek out and clear amyloid deposits in the brain.

In experiments using an Alzheimer's mouse model, the genetically modified astrocytes showed a significantly enhanced ability to remove amyloid-beta, and the amount of amyloid accumulated in the brain was markedly reduced. Notably, even a single early treatment was effective in preventing the formation of amyloid lesions.

The research team also confirmed through single-nucleus RNA analysis that CAR-A therapy not only affects astrocytes but also induces cooperation with microglia, thereby strengthening the glial cell response to amyloid pathology.

Experts evaluated this study as meaningful because it expands Alzheimer's treatment strategies beyond conventional antibody therapies into the realm of cell and gene therapies.

Professor Kim Chan-hyuk of the Department of Advanced Convergence Studies and the College of Pharmacy at Seoul National University explained to the Korea Science and Technology Media Center, "The strategy of removing amyloid-beta in Alzheimer's treatment has long been debated, but recently, antibody therapies have demonstrated clinical efficacy and become an important axis of treatment."

In fact, antibody therapies such as lecanemab and donanemab have recently shown effectiveness in slowing disease progression in early-stage Alzheimer's patients, leading to their approval. However, these treatments require high doses and have raised safety concerns, as some patients have experienced side effects such as brain inflammation.

Professor Kim said, "This study is distinguished from previous approaches in that it is a gene therapy strategy that reprograms astrocytes with a CAR gene to directly recognize and remove amyloid-beta, instead of relying on antibodies."

He also assessed, "CAR technology has mainly been used in cancer treatment and autoimmune diseases, so the attempt to extend its application to the treatment of degenerative brain diseases is also significant."

However, some point out that since the research is still at the animal testing stage, there are many technological barriers to overcome before it can be translated into actual treatment.

In particular, delivering genes to specific brain cells by crossing the blood-brain barrier (BBB) is extremely challenging. Further research is also needed on long-term safety, delivery efficiency, and cell selectivity.

Professor Kim stated, "While it is meaningful that the concept has been proven in mouse models, for it to be translated into human clinical applications, verification of delivery technology and long-term safety is essential." He also noted, "The lack of direct comparative data on efficacy and safety versus existing antibody therapies is another limitation."

Nonetheless, he emphasized, "It is significant that this study applied a CAR-based gene and cell therapy strategy to Alzheimer's treatment, as it offers a new direction for future research."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.